NSAIDs and acetaminophen are first-line for most chronic pain. For neuropathic pain, gabapentinoids (gabapentin, pregabalin), duloxetine, and tricyclic antidepressants have the best evidence. Opioids are a last resort due to poor long-term outcomes and serious risks — not a failing on the patient's part, but a reflection of what the evidence actually shows.
Medications for Chronic Pain: A Plain-English Guide
Chronic pain — pain lasting more than three months — affects roughly one in five adults and is one of the most undertreated and misunderstood medical conditions. The approach to treating it has changed dramatically over the past decade, driven by recognition that opioids, once widely prescribed for chronic non-cancer pain, have poor long-term outcomes for function and quality of life and carry serious risks. Understanding which medications are used for chronic pain, how they work, and what role opioids legitimately play helps patients advocate for appropriate care.
Chronic pain is not a single entity. Inflammatory pain (arthritis), neuropathic pain (nerve damage, diabetic neuropathy), and central sensitization (fibromyalgia) all involve different mechanisms — and they respond differently to medications. A drug that works well for one type may do little for another.
Drug Classes Used for Chronic Pain
NSAIDs are first-line for inflammatory chronic pain conditions — osteoarthritis, rheumatoid arthritis, ankylosing spondylitis — because they address the underlying inflammation driving pain. They work by blocking COX enzymes that produce prostaglandins, which sensitize pain receptors and promote inflammation. For short-term use, they are highly effective. The concern with chronic use is GI toxicity (ulcers, bleeding) and cardiovascular risk (increased heart attack and stroke risk, particularly COX-2 selective agents like celecoxib in high-risk patients). Long-term NSAID use requires monitoring and often a stomach-protective medication.
Acetaminophen is analgesic and antipyretic but not anti-inflammatory — it works through mechanisms not fully understood, involving inhibition of prostaglandin synthesis centrally and possibly endocannabinoid pathways. It is safer on the GI tract and cardiovascular system than NSAIDs, which makes it preferable for patients with GI or heart disease. However, liver toxicity is a real risk with amounts exceeding safe thresholds or in people who drink alcohol regularly. For osteoarthritis, acetaminophen is modestly effective; it does less for inflammatory arthritis. It remains widely recommended because its tolerability and safety profile make it suitable for long-term use when used appropriately.
Duloxetine has FDA approval for chronic musculoskeletal pain, diabetic peripheral neuropathy, and fibromyalgia — in addition to depression and anxiety. Its analgesic effect comes from norepinephrine (and to a lesser extent serotonin) modulation in descending pain pathways in the spinal cord, which normally suppress pain signals. This is entirely separate from its antidepressant effect — it works on pain even in patients without depression. Duloxetine is now considered a first- or second-line treatment for several chronic pain conditions in major guidelines. Venlafaxine has less pain-specific data but is sometimes used for neuropathic pain.
Gabapentin and pregabalin bind to voltage-gated calcium channels in the nervous system, reducing the release of pain-signaling neurotransmitters. They are FDA-approved for neuropathic pain conditions including postherpetic neuralgia (shingles nerve pain), diabetic peripheral neuropathy, and fibromyalgia (pregabalin). They are among the most prescribed medications for nerve pain. Side effects include sedation, dizziness, weight gain, and peripheral edema (swelling). Gabapentin in particular has expanded dramatically in prescribing scope beyond its approved uses; concerns about misuse potential and respiratory depression in combination with opioids have led to increased regulatory scrutiny.
Tricyclic antidepressants at lower amounts than used for depression are one of the best-established treatments for neuropathic pain. Amitriptyline is particularly well-studied for diabetic neuropathy, postherpetic neuralgia, and tension-type headache prevention. The mechanism involves blocking norepinephrine and serotonin reuptake in pain-modulating pathways, as well as sodium channel blockade. The side effect profile — sedation, dry mouth, constipation, urinary retention, cardiac conduction changes — limits their use, particularly in older adults. Nortriptyline has a somewhat better tolerability profile than amitriptyline.
Muscle relaxants reduce muscle spasm contributing to pain. Cyclobenzaprine is structurally similar to TCAs and works centrally, causing significant sedation. It is approved for short-term use in acute musculoskeletal conditions — there is limited evidence supporting long-term use, and the sedation and anticholinergic effects are problematic chronically. Baclofen is a GABA agonist used particularly for spasticity from neurological conditions (multiple sclerosis, spinal cord injury). Tizanidine is an alpha-2 agonist (similar mechanism to clonidine) used for spasticity with less sedation than baclofen for some patients.
Opioids work by binding to opioid receptors in the brain, spinal cord, and peripheral tissues, reducing the perception of pain and the emotional response to it. They are highly effective for acute pain and for cancer-related pain. For chronic non-cancer pain, the picture is far more complicated. Long-term data shows that many patients on chronic opioids experience opioid-induced hyperalgesia — a paradoxical increase in pain sensitivity from the opioids themselves. Physical dependence develops within weeks; tolerance requires increasing amounts for the same effect; addiction risk exists. Current CDC and most specialty guidelines recommend opioids for chronic non-cancer pain only after multiple other treatments have failed, at the lowest effective amount, with regular reassessment of benefit.
Why Opioids Are Not First-Line for Chronic Pain
This is not a political statement — it reflects what the clinical evidence shows. Several large, long-term studies have demonstrated that patients with chronic pain on long-term opioids do not have better function or quality of life than patients on non-opioid treatment. Physical dependence means patients cannot stop without withdrawal. Tolerance means the amounts needed escalate over time. Opioid-induced hyperalgesia can actually worsen pain. And overdose risk — especially in combination with benzodiazepines, alcohol, or in the context of accidental misuse — is real and deadly.
None of this means opioids are never appropriate for chronic pain. They remain a legitimate option for specific patients — those with severe pain from conditions like cancer, sickle cell disease, or advanced degenerative joint disease — when risks are carefully weighed. The key is that the risk-benefit calculation for opioids in chronic non-cancer pain is much less favorable than it was once believed, and that many non-opioid options work well and are safer for long-term use.
Never combine opioids with benzodiazepines, alcohol, or other CNS depressants without explicit medical guidance. This combination dramatically increases the risk of respiratory depression and overdose. Naloxone (Narcan) should be available in any household where opioids are present.
Frequently Asked Questions
Why aren't opioids prescribed first for chronic pain?
Opioids carry significant risks including physical dependence, tolerance, overdose, and opioid-induced hyperalgesia (worsening pain). For many chronic pain conditions, long-term outcomes data shows opioids do not improve function or quality of life better than non-opioid alternatives, which often have a far safer long-term profile. Current guidelines recommend exhausting non-opioid approaches first.
Why do antidepressants help chronic pain?
Certain antidepressants — particularly SNRIs like duloxetine and TCAs like amitriptyline — have direct analgesic properties unrelated to their mood effects. They modulate descending pain pathways in the spinal cord through norepinephrine signaling that normally inhibits pain transmission. This is why they help neuropathic pain even in patients without depression.
What is the difference between nociceptive and neuropathic pain?
Nociceptive pain comes from actual or potential tissue damage — an inflamed joint or injured muscle. NSAIDs and acetaminophen work best here. Neuropathic pain arises from damage or dysfunction of the nervous system itself — diabetic nerve pain, post-herpetic neuralgia, or radiculopathy. Neuropathic pain responds poorly to NSAIDs and much better to gabapentinoids, SNRIs, and TCAs. Correctly identifying the pain type is essential to choosing effective treatment.
Need to identify a pill by its imprint, shape, or color?
Use the PillID Pill Identifier →